Elevai Labs INC S-1 registration statements

PMGC Holdings Inc. filed an S-1/A registration statement for the resale of up to 5,000,000 shares of common stock by selling security holders, while detailing recent acquisitions and an equity line of credit.

PMGC Holdings Inc. filed an S-1/A detailing its transformation into a diversified holding company with a focus on biotechnology and manufacturing acquisitions, alongside significant capital raising activities.

PMGC Holdings Inc. filed an S-1 registration statement for the resale of up to 5 million common shares by Streeterville Capital, LLC, following a new $20 million equity line of credit and recent strategic acquisitions.

PMGC Holdings Inc. filed an S-1/A, outlining recent capital raises, strategic acquisitions in manufacturing and biotech, and a continued focus on its diversified portfolio despite ongoing financial losses.

PMGC Holdings Inc. filed an S-1 registration statement for the resale of up to 236,543 common shares underlying warrants, seeking to raise approximately $1.56 million from warrant exercises while grappling with significant net losses and going concern doubts.

PMGC Holdings Inc. has filed an amendment to its Form S-1 registration statement to register the resale of up to 559,261 shares of common stock underlying warrants issued to selling shareholders.

Elevai Labs Inc. has established a non-exclusive authorized distributor agreement with Refine USA, LLC for its skincare products in the United States.

Elevai Labs Inc. is seeking to raise capital through a public offering of common stock and warrants to fund general corporate purposes and maintain Nasdaq compliance.

Elevai Labs Inc. files an amendment to its Form S-1 registration statement for a public offering of common stock and warrants, aiming to raise capital while addressing Nasdaq listing deficiencies.

Elevai Labs Inc. aims to raise up to $8 million through a public offering of common stock, pre-funded warrants, and accompanying Series A and Series B warrants.